Genomic Discovery of EF-24 Targets Unveils Antitumorigenic Mechanisms in Leukemia Cells
Preprint
Abstract
Curcumin, a polyphenolic compound derived from the plant Curcuma longa L., has demonstrated a wide range of therapeutic properties, including potential anticancer effects. However, its clinical efficacy is limited due to poor bioavailability and stability. To overcome these challenges, curcumin analogs like EF-24 have been developed with improved pharmacological properties. In this study, we used whole-transcriptome profiling to identify the genome-wide functional impacts of EF-24 treatment in leukemia cells to improve our understanding of its potential mechanisms of action. This approach allowed us to establish a model system for associating druggable genes with clinical disease targets. We used the chronic myeloid leukemia (CML) cell line K-562 and acute myeloid leukemia (AML) cell lines HL-60, Kasumi-1, and THP-1 to conduct EF-24 treatment studies. Cell viability was significantly decreased in the EF-24–treated cells as compared to the untreated controls. We discovered that the genes ATF3, CLU, HSPA6, OSGIN1, ZFAND2A, and CXCL8, which are associated with reduced cell viability and proliferation, were consistently upregulated in all EF-24–treated cell lines. Further analysis of the tested cell lines revealed the activation of various signaling pathways, including the STAT1 regulated S100 family signaling pathway, that controlled downstream gene expression in response to EF-24 treatment. Our results elucidate the molecular mechanisms underlying EF-24’s antitumor efficacy against leukemia, highlighting its multifaceted impact on signaling pathways and gene networks that regulate cell survival, proliferation, and immune responses in myeloid leukemia cells. Significance: This study reveals how EF-24, a curcumin analog, disrupts key signaling pathways in chronic and acute myeloid leukemia cell lines, offering insights to enhance targeted therapies and provide new targets for investigation. Conflict of Interest Statement: The authors declare no potential conflicts of interest.Keywords
This publication has 60 references indexed in Scilit:
- PHLDA2-mediated phosphatidic acid peroxidation triggers a distinct ferroptotic response during tumor suppressionCell Metabolism, 2024
- MLC1 Overexpression Inhibits Tumor Progression through PI3K/AKT Signal Pathway in Prostate CancerAdvanced Biology, 2023
- STING-mediated degradation of IFI16 negatively regulates apoptosis by inhibiting p53 phosphorylation at serine 392Journal of Biological Chemistry, 2021
- The ‘cytokine storm’: molecular mechanisms and therapeutic prospectsTrends in Immunology, 2021
- Targeting immunogenic cell death in cancerMolecular Oncology, 2020
- Neutrophils in the Tumor Microenvironment2020
- A network map of Interleukin-10 signaling pathwayJournal of Cell Communication and Signaling, 2015
- Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinomaHepatology, 2013
- Human nuclear clusterin mediates apoptosis by interacting with Bcl‐XL through C‐terminal coiled coil domainJournal of Cellular Physiology, 2011
- Clusterin and DNA repair: a new function in cancer for a key player in apoptosis and cell cycle controlJournal of Molecular Histology, 2006